New Study Highlights the Utility of the FebriDx® Test for Rapid Triage and Identification of COVID-19September 17, 2020
Lumos Diagnostics today announced the publication of a COVID-19 (SARS-CoV-2) clinical trial in The International Journal of Clinical Practice. Kettering General Hospital in the UK prospectively performed a clinical assessment of the FebriDx® point-of-care (POC) fingerstick blood test to rapidly assess and differentiate viral from bacterial symptomatic respiratory infections. The study concluded that FebriDx could be deployed as part of a reliable triage strategy for identifying symptomatic cases as possible COVID-19 in the pandemic.
FebriDx® Test Featured in UK National Institute for Health and Care Excellence (NICE) Medtech Innovation Briefing (MIB)
Lumos Diagnostics rapid point-of-care (POC) FebriDx® test was featured in a Medtech Innovation Briefing (MIB), as part of the United Kingdom’s National Institute for Health and Care Excellence (NICE) guidance for the COVID-19 pandemic response. This MIB addresses the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises.
A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled "Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19" identifies the FebriDx® test as a rapid, highly accurate, and affordable 'front door triage tool' to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19.
A peer-reviewed article just published in the Annals of Medicine titled "Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic" describes an algorithm for sustainable testing capacity to efficiently evaluate patients in response to a pandemic.
A new study just published in the Journal of Medical Economics found that the FebriDx® test could save the UK healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.
Lumos Diagnostics Supports the Victorian Healthcare System by Providing FebriDx® for a Pilot Evaluation in the Triaging of Acute Respiratory Infection Patients
Lumos Diagnostics supports the Victorian healthcare system by providing FebriDx® for a pilot evaluation in the triaging of acute respiratory infection patients
Lumos Diagnostics, a point-of-care diagnostic test developer, manufacturer and marketer, secured U.S. $15 million in Series A funding from Planet Innovation, an Australia-based healthtech innovation and commercialization company.
Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.